530 related articles for article (PubMed ID: 21107285)
41. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
42. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma.
Kang HJ; Lim HJ; Park JS; Cho YJ; Yoon HI; Chung JH; Lee JH; Lee CT
Respir Med; 2014 Feb; 108(2):388-94. PubMed ID: 24361161
[TBL] [Abstract][Full Text] [Related]
43. ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes.
Caliò A; Bria E; Pilotto S; Gilioli E; Nottegar A; Eccher A; Cima L; Santo A; Pedron S; Turri G; Knuutila S; Chilosi M; Vanzo F; Bogina G; Terzi A; Tortora G; Scarpa A; Loda M; Martignoni G; Brunelli M
Cancer Biomark; 2017; 18(2):215-220. PubMed ID: 28009326
[TBL] [Abstract][Full Text] [Related]
44. Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.
Zhao F; Xu M; Lei H; Zhou Z; Wang L; Li P; Zhao J; Hu P
PLoS One; 2015; 10(2):e0117333. PubMed ID: 25706305
[TBL] [Abstract][Full Text] [Related]
45. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
Zhang X; Zhang S; Yang X; Yang J; Zhou Q; Yin L; An S; Lin J; Chen S; Xie Z; Zhu M; Zhang X; Wu YL
Mol Cancer; 2010 Jul; 9():188. PubMed ID: 20624322
[TBL] [Abstract][Full Text] [Related]
46. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
[No Abstract] [Full Text] [Related]
47. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
[TBL] [Abstract][Full Text] [Related]
48. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
Tsuta K; Kozu Y; Mimae T; Yoshida A; Kohno T; Sekine I; Tamura T; Asamura H; Furuta K; Tsuda H
J Thorac Oncol; 2012 Feb; 7(2):331-9. PubMed ID: 22198430
[TBL] [Abstract][Full Text] [Related]
49. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
[TBL] [Abstract][Full Text] [Related]
50. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
51. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
52. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
53. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.
Dziadziuszko R; Merrick DT; Witta SE; Mendoza AD; Szostakiewicz B; Szymanowska A; Rzyman W; Dziadziuszko K; Jassem J; Bunn PA; Varella-Garcia M; Hirsch FR
J Clin Oncol; 2010 May; 28(13):2174-80. PubMed ID: 20351332
[TBL] [Abstract][Full Text] [Related]
54. Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: a novel ALK fusion gene?
Yamamoto M; Takeuchi K; Shimoji M; Maniwa T; Isaka M; Nakagawa K; Ohde Y; Kondo H; Nakajima T
Cancer Sci; 2012 Feb; 103(2):390-2. PubMed ID: 22296236
[TBL] [Abstract][Full Text] [Related]
55. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
56. Clinicopathological features and diagnostic methods of ALK fusion‑positive non‑small cell lung cancer in Korea.
Chang WC; Kim HK; Shin BK
Oncol Rep; 2020 Jan; 43(1):218-228. PubMed ID: 31746406
[TBL] [Abstract][Full Text] [Related]
57. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
Won JK; Keam B; Koh J; Cho HJ; Jeon YK; Kim TM; Lee SH; Lee DS; Kim DW; Chung DH
Ann Oncol; 2015 Feb; 26(2):348-54. PubMed ID: 25403583
[TBL] [Abstract][Full Text] [Related]
58. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
59. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.
Tiseo M; Gelsomino F; Boggiani D; Bortesi B; Bartolotti M; Bozzetti C; Sammarelli G; Thai E; Ardizzoni A
Lung Cancer; 2011 Feb; 71(2):241-3. PubMed ID: 21168933
[TBL] [Abstract][Full Text] [Related]
60. Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer.
Schoppmann SF; Streubel B; Birner P
Eur J Cancer; 2013 May; 49(8):1876-81. PubMed ID: 23490651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
